Stroke related to large vessel occlusion is a leading cause of disability and death worldwide.
Advances in endovascular therapy to reopen occluded arteries have been shown to reduce …

A decade on from the first positive thrombectomy trials, hyperacute therapies for ischemic
stroke continue to rapidly advance. Effective treatments remain limited to reperfusion …

Background Dissecting trends and contributing risk factors for intracranial hemorrhage (ICH)
in patients treated for acute pulmonary embolism (PE) may allow for a better patient …

Intravenous thrombolysis (IVT) and dual antiplatelet therapy (DAPT) have been widely used
in minor ischemic stroke (MIS) treatment. However, the clinical outcomes and safety of these …

Every year close to 700,000 people experience a new or recurrent ischemic stroke in the
United States, and 3% of the total US population is affected by stroke. 1 Stroke is the leading …

Five-phase 3 randomized controlled trials have demonstrated noninferiority of tenecteplase
versus alteplase 0 to 4.5 hours after stroke onset. 5–10 In the study-level metaanalysis …

Current Opinion in Neurology Log in or Register Subscribe to journalSubscribe Get new issue
alertsGet alerts Secondary Logo Journal Logo Advanced Search Toggle navigation Subscribe …

Mild stroke symptoms are cited as the reason for not using tissue-type plasminogen activator
in 29–43% of time-eligible patients. Previous studies suggested that not all of these patients …

Recent clinical trials provide robust evidence of non-inferiority of tenecteplase 0.25 mg/kg
over alteplase 0.9 mg/kg in acute ischemic stroke treated within 4.5 h of time last known well …

Background The benefits of intravenous thrombolysis in patients with acute minor stroke
remain controversial. For the aim of providing a better therapeutic strategy, high-quality trials …